DXB
Director Trades
| Date | Director | Value |
|---|
Company News
Dimerix Reports Positive Data Supporting Action3 Study of DMX-200 to Treat Kidney Disease
Dimerix (ASX: DXB) has received final data analysis from the international PARASOL collaboration that reinforces support for proteinuria-based endpoints in its pivotal Phase 3 Action3 study on DMX-200 for the treatment of kidney disease. The multi-centre, randomised, double-blind, placebo-controlled study is testing the drug’s efficacy and safety in patients with focal segmental glomerulosclerosis (FSGS) who are […]
Dimerix and Amicus Therapeutics partner to commercialise kidney disease treatment DMX-200 in the US
Drug developer Dimerix (ASX: DXB) and US biopharmaceuticals company Amicus Therapeutics have entered into an exclusive US licence agreement for the commercialisation of Dimerix’s lead candidate DMX-200. The drug is under development in a pivotal Phase 3 study known as ACTION3 for the treatment of rare-but-fatal kidney disease focal segmental glomerulosclerosis (FSGS). Under the terms […]
Market wrap: ASX 200 closes below 7000-point mark despite a tentative recovery
The Australian share market took a couple of tentative steps in the upwards direction after a tough week in which the ASX 200 fell decisively below the important 7000-point mark. By the Friday close the index had limped upwards 0.4% or 28.7 points to 6,954.2 points after two positive days which followed on from a […]
Dimerix secures deal to commercialise DMX-200 for treatment of rare kidney disease
Drug development company Dimerix (ASX: DXB) has secured a licencing deal with Advanz Pharma Corp for the commercialisation of Dimerix’s Phase 3 drug candidate DMX-200 to treat focal segmental glomerulosclerosis (FSGS) kidney disease. The agreement will give Advanz exclusive rights to register and market the drug in the European Economic Area, UK, Switzerland, Canada, Australia […]
ASX biotech stocks benefiting from the COVID-19 story
Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks across the drug, diagnostics and device sectors. Naturally, the biotechs drawing a connection with fighting or detecting the virus – spurious or otherwise – have seen their valuations soar. Not that investor interest is […]
Dimerix unveils ‘tremendous’ top-line results for lead drug in treating rare kidney disorder
Drug development company Dimerix (ASX: DXB) emerged from a trading halt today with top-line results from its phase 2a ACTION study into DMX-200 for treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder that often leads to end-stage kidney failure. Dimerix received orphan drug designation for DMX-200 in November 2018 in both the US […]
Dimerix’s lead drug candidate to be included in key clinical study for COVID-19 respiratory patients
A lead drug candidate developed by clinical-stage biopharmaceutical company Dimerix Limited (ASX: DXB) has been selected for inclusion in a global study aimed at treating patients with acute respiratory distress syndrome (ARDS) as a result of COVID-19. The randomised, embedded, multifactorial adaptive platform trial for community-acquired pneumonia (or REMAP-CAP) program will focus on a number […]
Patients continue Dimerix’s DMX-200 treatment post-trial under TGA scheme
Clinical-stage biopharmaceutical company Dimerix (ASX: DXB) received an operational boost earlier today after announcing that patients from phase 2 trials will continue treatment with its DMX-200 adjunct therapy under Australia’s Therapeutic Goods Administration’s compassionate use special access scheme (SAS). In the phase 2 clinical trials, patients suffering from diabetic kidney disease and focal segmental glomerulosclerosis (FSGS) […]
Dimerix targets ‘important new drug discovery’ in the treatment of chronic obstructive pulmonary disease
Clinical-stage biopharmaceutical company Dimerix (ASX: DXB) has announced plans to target the development of what it calls “an important new discovery” in the treatment of chronic obstructive pulmonary disease (COPD). The DMX-700 drug was identified using Dimerix’s proprietary Receptor-HIT cell-based assay and if successful, will meet a significant unmet medical need in the pharmaceutical industry. […]
Dimerix receives orphan drug designation in Europe for DMX-200
Drug development company Dimerix (ASX: DXB) has confirmed that the European Commission (EC) has approved its DMX-200 drug to be used as an “orphan medicinal product” for the treatment of Focal Segmental Glomerulosclerosis (FSGS), a form of chronic kidney disease that is currently the leading cause of kidney failure in adults globally. Orphan designation is […]
